Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTS071 in Advanced Solid Tumors With TP53 Y220C Mutation
NCT07060989Phase 2Recruiting
- Sponsor
- NUTSHELL Therapeutics
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of NTS071 in solid tumor, sponsored by NUTSHELL Therapeutics. Started Aug 2025; status: recruiting.
02
Drugs
NTS071
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07060989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060989.